With the deep knowledge of Mdm2-p53 in cancer biology, our research could rapidly facilitate the study of, or even future treatment for, neurologic diseases associated with constitutively active Gp1 mGluR signaling. This evidence concerns the gene GTPBP1 and nervous system disorder.